Spinach Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.50 Cr
- Company Age 11 Year, 4 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 3.80 Cr
- Revenue Growth %
- Profit Growth -4141.50%
- Ebitda -3882.42%
- Net Worth -45.59%
- Total Assets -2.07%
About Spinach Pharma
Spinach Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 September 2013 and has a history of 11 years and four months. Its registered office is in Vellore, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹3.80 Cr.
Ettya Venkatesan, Cheyyanur Kesavamurthy, Natarajan Selvam, and One other member serve as directors at the Company.
Company Details
-
Location
Vellore, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24233TN2013PTC093187
-
Company No.
093187
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Sep 2013
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Spinach Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Natarajan Selvam
|
Director | 01-Sep-2014 | Current |
|
Ettya Venkatesan
|
Director | 30-Sep-2013 | Current |
|
Cheyyanur Kesavamurthy
|
Director | 30-Sep-2013 | Current |
|
Kalipillai Shanmugam
|
Director | 01-Sep-2014 | Current |
Financial Performance of Spinach Pharma.
Spinach Pharma Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 4141.5% decrease in profit. The company's net worth observed a substantial decline by a decrease of 45.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Spinach Pharma?
In 2017, Spinach Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Reach Today Media Private LimitedEttya Venkatesan is a mutual person
Charges (Loans)
₹3.80 Cr
₹0
Charges Breakdown by Lending Institutions
- Andhra Bank : 3.80 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Oct 2015 | Andhra Bank | ₹3.80 Cr | Open |
How Many Employees Work at Spinach Pharma?
Unlock and access historical data on people associated with Spinach Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Spinach Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Spinach Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.